Mirna Therapeutics

Mirna’s lead product candidate, MRX34, is the first microRNA mimic to enter clinical development in oncology. MRX34 is being studied as a single agent in our ongoing open-label, multicenter Phase 1 clinical trial, which has included patients with primary liver cancer, other solid cancers, and hematological malignancies (lymphomas and leukemias). MRX34 was designed to deliver a mimic of the naturally occurring microRNA tumor suppressor miR-34, which is under expressed in a wide variety of cancers. MRX34 entered clinical testing in 2013.

Type
Public
HQ
Austin, US
Employees
33 (est)
Mirna Therapeutics is headquartered in Austin, US

Key People at Mirna Therapeutics

Sinil Kim

Sinil Kim

Vice President Oncology & Chief Medical Officer
Jon Irvin

Jon Irvin

CFO
David Brown

David Brown

Director, Discovery and in vivo Research
Andreas Bader

Andreas Bader

Director, Analytical and External Research
Neil Leatherbury

Neil Leatherbury

Director, Pharmaceutical Development
Paul Lammers

Paul Lammers

President & CEO

Mirna Therapeutics Locations

Austin, US

Mirna Therapeutics Metrics

Mirna Therapeutics Summary

Market capitalization

$32.7 M

Closing share price

$1.58
Mirna Therapeutics's latest market capitalization is $32.7 M.

Mirna Therapeutics Market Value History

Mirna Therapeutics News

Mirna Therapeutics Company Life

You may also be interested in